Cost-effectiveness and budget impact of lung cancer screening in time of immunotherapy
Lung cancer screening in high-risk population remains cost-effective when immunotherapy is offered to all stages. By shifting diagnoses from advanced to early stages, screening yielding substantial savings. These findings support LDCT screening implementation even in healthcare systems broadly using immunotherapy.
Authors
- Keris Poelhekken (ORCID: https://orcid.org/0000-0001-8884-1936)
- Yihui Du (ORCID: https://orcid.org/0000-0003-0959-8339)
- Rozemarijn Vliegenthart (ORCID: https://orcid.org/0000-0002-7262-3376)
- Marcel J. W. Greuter (ORCID: https://orcid.org/0000-0001-5721-9159)
- Karin M. Vermeulen (ORCID: https://orcid.org/0000-0001-9257-2791)
- Marjolein A. Heuvelmans (ORCID: https://orcid.org/0000-0002-5712-4085)
- Harry J.M. Groen (ORCID: https://orcid.org/0000-0002-2978-5265)
- Geertruida H. de Bock (ORCID: https://orcid.org/0000-0003-3104-4471)
- Grigory Sidorenkov (ORCID: https://orcid.org/0000-0002-1926-8862)
- Danrong Zhong (ORCID: https://orcid.org/0009-0004-1111-6874)
Institutions
- University Medical Center Groningen (NL)
- Hangzhou Normal University (CN)
- University of Groningen (NL)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108669
- Citations
- 2
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- China Scholarship Council